14.09.2016

Neovii Pharmaceuticals AG licenses worldwide (excluding U.S. & Japan) developmental and commercialization rights for ARCALYST® (rilonacept) from Regeneron for the treatment of periodic fever syndromes

September 14, 2016

Neovii Pharmaceuticals AG licenses worldwide (excluding U.S. & Japan) developmental and commercialization rights for ARCALYST® (rilonacept) from Regeneron for the treatment of periodic fever syndromes

RAPPERSWIL, SWITZERLAND, September 14, 2016 — Neovii Pharmaceuticals AG announced today a licensing and supply agreement with U.S.-based Regeneron Pharmaceuticals, Inc. to develop and commercialize Regeneron’s interleukin-1 inhibitor ARCALYST® (rilonacept) for the potential treatment of periodic fever syndromes in all markets excluding the United States and Japan. ARCALYST is currently approved in the United States for the treatment of adults and children aged 12 and older with Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells syndrome (MWS).

Periodic Fever Syndromes are a group of diseases including CAPS and Familial Mediterranean Fever (FMF), that are characterized by inflammation in many parts of the body, with symptoms such as rash, fever or chills, joint pain, eye redness/pain and fatigue. Severe disabilities such as deafness and loss of vision may occur in certain cases.

Neovii’s Chief Executive Officer Alexandre Sudarskis commented, “We are very excited with this agreement which supports our mission to bring life-transforming therapies to treat patients with unmet needs around the world. Our initial focus will be on Familial Mediterranean Fever, which has a high incidence in the Mediterranean region particularly among people of Arab, Armenian, Israeli or Turkish ancestry.”

“While these conditions are rare, there are patients across the globe in desperate need of new treatment options,” said Nouhad Husseini, Vice President, Business Development at Regeneron. “Neovii’s development of ARCALYST will potentially enable expanded global access and treatment for additional conditions, benefiting many families impacted by these difficult diseases.”

Financial terms of the deal were not disclosed.

About the Familial Mediterranean Fever

Familial Mediterranean Fever is an inherited condition characterized by recurrent episodes of painful inflammation in the abdomen, chest or joints. These episodes are often accompanied by fever and sometimes a rash or headache. Occasionally inflammation may occur in other parts of the body, such as the heart, the membrane surrounding the brain and the spinal cord. The disorder affects 1 in 200 to 1,000 people in populations of Arab, Armenian, Israeli or Turkish ancestry.” It is less common in other populations.

About Neovii

Neovii is an independent, dynamic and rapidly-growing global biopharmaceutical company with patient-focused mission to develop and market novel life-transforming therapies. Neovii has been dedicated for over three decades to improve the outcomes in transplantation medicine, hemato-oncological and immune disorders.

Neovii Pharmaceuticals AG global headquarters is in Rapperswil, Switzerland, with offices in Massachusetts, USA and its biologics manufacturing facility is in Gräfelfing, Germany.

Neovii has a global reach with products sold in over 50 countries worldwide.

For further information

For further information please visit www.neovii.com

Your Media Contact on behalf of Neovii is Daniela Suter@bm.com

You can find a PDF of the press release here.